SciSparc (SPRC) Interest Expenses (2016 - 2022)
SciSparc's (SPRC) quarterly Interest Expenses came in at $2.0 million in Q4 2022, up 1619.83% quarter-over-quarter from $116000.0 in Q4 2018.
Powered by 
Analysis
SciSparc (SPRC) Interest Expenses (2016 - 2022) Analysis & Trends
SciSparc has disclosed Interest Expenses across 4 years of filings, most recently posting $2.0 million for Q4 2022.
- In Q4 2022, Interest Expenses changed N/A year-over-year to $2.0 million; the TTM figure through Dec 2022 stood at $2.1 million (changed N/A YoY), while the FY2025 annual figure was $8.2 million, up 2222.66% from the prior year.
- Interest Expenses came in at $2.0 million for Q4 2022 at SciSparc, up from $116000.0 in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $2.0 million in Q4 2022 to a low of $1000.0 in Q2 2018.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn | 281.00 Mn |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn | - |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn | -462.00 Mn |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | - |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn | -333.60 Mn |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - | 23.78 Mn |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn | 582,000.00 |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn | 2.90 Mn |
| 10 | SciSparc | 614,715.73 | 614,715.73 | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2022 | 2.00 Mn |
| Dec 31, 2018 | 116,000.00 |
| Sep 30, 2018 | 11,000.00 |
| Jun 30, 2018 | 1,000.00 |
| Mar 31, 2018 | 2,000.00 |
| Dec 31, 2017 | 142,000.00 |
| Sep 30, 2017 | -79,000.00 |
| Jun 30, 2017 | 437,000.00 |
| Dec 31, 2016 | -8,000.00 |
| Sep 30, 2016 | 10,000.00 |